WS Audiology looks to new OTC market – but won't disclose plans

As competitors are arming themselves with products designed for the upcoming OTC sales channel in the US, WSA keeps a tight lid on plans. The new market will start out messy, says CEO Eric Bernard, but it will stabilize eventually.
Eric Bernard, CEO of WS Audiology | Photo: WS Audiology / PR
Eric Bernard, CEO of WS Audiology | Photo: WS Audiology / PR

On Thursday, WS Audiology could present the best quarterly report since the company was founded when Sivantos and Widex merged in 2019.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading